Cytokinetics, Inc.
662 articles about Cytokinetics, Inc.
-
Cytokinetics, Inc. to Present Clinical Data Relating to CK-2017357 at the 22nd Annual Sessions of the Society for Vascular Medicine
5/27/2011
-
Cytokinetics, Inc. to Hold Annual Meeting of Stockholders
5/12/2011
-
Cytokinetics, Inc., Incorporated Reports First Quarter 2011 Financial Results
4/28/2011
-
Cytokinetics, Inc. to Present at May Healthcare Conferences
4/26/2011
-
Cytokinetics, Inc. to Announce First Quarter Results on April 27, 2011
4/21/2011
-
Cytokinetics, Inc. Announces Opening of Phase 2 Clinical Trial of Intravenous Formulation of Omecamtiv Mecarbil in Patients With Acute Heart Failure
4/19/2011
-
Cytokinetics, Inc., Incorporated Announces $20 Million Financing
4/18/2011
-
Cytokinetics, Inc. Announces Presentation of Data From a Phase 2a Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis at the 63rd Annual Meeting of the American Academy of Neurology
4/18/2011
-
Cytokinetics, Inc. Announces Fundamental Research in the Field of Cardiac Myosin Activation Published in the Journal Science
3/18/2011
-
Cytokinetics, Inc. to Present at March Healthcare Conferences
2/23/2011
-
Cytokinetics, Inc., Incorporated Reports Fourth Quarter and Year End Highlights and 2010 Financial Results
2/15/2011
-
Cytokinetics, Inc. Loses $11.6 Million in Q4
2/15/2011
-
Cytokinetics, Inc. Announces Changes to Its Board of Directors, Dr. Wendell Wierenga Elected
2/11/2011
-
Cytokinetics, Inc. Provides Update Regarding Omecamtiv Mecarbil Clinical Development Program
2/9/2011
-
Cytokinetics, Inc. to Announce Fourth Quarter and Year End 2010 Results on February 14, 2011
2/8/2011
-
Cytokinetics, Inc. to Present at Biotechnology Industry Organization (BIO) CEO and Investor Conference
2/7/2011
-
Cytokinetics, Inc. Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Myasthenia Gravis
1/4/2011
-
Cytokinetics, Inc. to Present at the Deutsche Bank BIOFest Conference
12/14/2010
-
Cytokinetics, Inc. Stock Plunges 21.5% as of 1:58PM EST After Phase II Results Released
12/14/2010
-
Cytokinetics, Inc. Drug Helps ALS Patients in Small Trial
12/13/2010